XL 999

Drug Profile

XL 999

Alternative Names: EXEL-0999; XL-999

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Exelixis
  • Developer Exelixis; Symphony Capital Partners
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Platelet-derived growth factor beta receptor antagonists; Type 1 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer
  • Discontinued Acute myeloid leukaemia; Colorectal cancer; Multiple myeloma; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Cancer in USA (IV, Infusion)
  • 11 Jun 2007 Data presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2007) added to the adverse events and Cancer therapeutic trials sections
  • 07 Nov 2006 Clinical data from a media release have been added to the adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top